Evidence map›Paper›PMID 22367345›Full record

Trial reportBone marrow transplantation2012

Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors.

K Taniguchi, S Yoshihara, E Maruya, K Ikegame, K Kaida, K Hayashi, R Kato, T Inoue, T Fujioka, H Tamaki and 7 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. PosttransplantFrontiers in immunology · 2022
    Article
  3. HLA Matching in Unrelated Stem Cell Transplantation up to Date.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019
    Review
  4. Article
  5. Review
  6. Article
  7. Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

K TaniguchiDepartment of Internal Medicine, Division of Hematology, Hyogo College of Medicine, Hyogo, Japan.
S Yoshihara
E Maruya
K Ikegame
K Kaida
K Hayashi
R Kato
T Inoue
T Fujioka
H Tamaki
M Okada
T Onuma
N Fujii
Y Kusunoki
T Soma
H Saji
H Ogawa
Hyogo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-existing donor-specific HLA antibodies in patients undergoing HLA-mismatched SCT have increasingly been recognized as a risk factor for primary graft failure. However, the clinical implications of the presence of HLA antibodies in donors remain unknown. We prospectively examined 123 related donors for the presence of HLA antibodies by using a Luminex-based single antigen assay. Of these, 1/57 (1.8%) male, 6/27 (22%) parous female and 0/39 (0%) nonparous female donors were HLA antibody-positive. Then, we determined the presence of HLA antibodies in seven patients who received SCT from antibody-positive donors. Of these, four became HLA antibody-positive after SCT. The specificities of the antibodies that emerged in the patients closely resembled those of the antibodies found in the donors, indicating their production by donor-derived plasma cells. Moreover, the kinetics of the HLA antibody levels were similar in all four patients: levels started increasing within 1 week after SCT and peaked at days 10-21, followed by a gradual decrease. These results suggest that donor-derived HLA antibody production frequently occurs in patients undergoing SCT from antibody-positive donors. Further studies are warranted for clarifying the clinical significance of donor-derived HLA antibodies, including the role of these antibodies in post transplant platelet transfusion refractoriness.

Indexed as

HLA AntigensStem Cell TransplantationUnrelated DonorsAdultFemaleHumansIsoantibodiesMaleMiddle AgedPlasma CellsProspective StudiesSiblingsTime FactorsHLA AntigensIsoantibodies

Identifiers

PMID22367345
OpenAlexW2054765412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.